WO2010109611A1

WO2010109611A1 - Pharmaceutical composition container

Info

Publication number: WO2010109611A1
Application number: PCT/JP2009/055973
Authority: WO
Inventors: 修司盛本
Original assignee: 株式会社モリモト医薬
Priority date: 2009-03-25
Filing date: 2009-03-25
Publication date: 2010-09-30
Also published as: JPWO2010110367A1; WO2010110367A1

Abstract

Disclosed is a pharmaceutical composition container, which can easily store a plurality of kinds of pharmaceutical compositions for a long period of time and can easily mix the pharmaceutical compositions as needed. A pharmaceutical composition container (10) has at least three spaces (30, 32, 34, 36) within a container body (20). A portion (140, 142, 144) between adjacent two spaces is closed. The portion (140, 142, 144) between the adjacent two spaces is opened upon exposure to a force from the outside of the pharmaceutical composition container (10). A fluid material (40) is contained in a fluid material chamber (30) that is at least one of the spaces. Different kinds of pharmaceutical compositions (80, 82) are respectively contained in pharmaceutical composition chambers (34, 36) that are at least two of the spaces.

Description

Pharmaceutical composition container

The present invention relates to a pharmaceutical composition container, and more specifically, a pharmaceutical composition container which can easily store a plurality of types of pharmaceutical compositions over a long period of time and can easily mix these pharmaceutical compositions as needed. About.

Patent Document 1 discloses a multi-chamber container. This multi-chamber container partitions a plurality of spaces so as to communicate with each other. These spaces are closed in a state where they can communicate with each other by a force applied from the outside. In any of these spaces, the granular agent is accommodated in a sealed state. The other space contains a dense fluid substance in a sealed state. Each space is communicated with each other, and after the granular material and the concentrated fluid substance are collected and mixed, the mixture can be taken out from a take-out port provided in any one of the spaces.

According to the container disclosed in Patent Document 1, it is possible to take the granular agent by an extremely simple operation. In addition, according to the multi-chamber container disclosed in Patent Document 1, the patient's resistance to taking can be greatly reduced.
Japanese Patent Laid-Open No. 10-234820

However, in the invention disclosed in Patent Document 1, there is a problem that there is a concern about the quality change of the granular agent accommodated in the multi-chamber container. This problem is exacerbated when the granulate consists of a mixture, compared to when it is not. The problem becomes serious because in the case of a mixture, a plurality of chemical substances as components may cause a chemical reaction. Due to concerns about such problems, in Japan, it is obliged to test in advance whether or not alteration occurs during distribution of the drug or storage of the drug. This is one of the causes of the extremely long time taken from drug development to distribution.

The technical problem of the present invention has been made to solve the above-mentioned problems, and the object thereof is to easily store a plurality of types of pharmaceutical compositions over a long period of time, and to prepare these pharmaceutical compositions. The object is to provide a pharmaceutical composition container which can be easily mixed at any time.

The pharmaceutical composition container of the present invention will be described with reference to the drawings. Note that the use of the reference numerals in the figure in this column is intended to assist understanding of the contents of the invention, and is not intended to limit the contents to the illustrated range.

In order to achieve the above object, according to one aspect of the present invention, the pharmaceutical composition container 10 includes at least three

spaces

30, 32, 34, and 36 in the container body 20. Between two

adjacent spaces

140, 142, and 144 are closed. The

space

140, 142, 144 between two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container 10. A fluid substance 40 is accommodated in a fluid substance chamber 30 which is at least one of the spaces. Different types of

pharmaceutical compositions

80 and 82 are accommodated in the

pharmaceutical composition chambers

34 and 36 which are at least two of the spaces.

Between the two

adjacent spaces

140, 142, 144 are closed. Since it is occluded, the

pharmaceutical compositions

80 and 82 contained in the

pharmaceutical composition chambers

32 and 34, respectively, are not mixed. Since they do not mix, they do not cause a chemical reaction or one dissolves in the other. Thereby, it is unlikely that they will be altered. Since they are unlikely to be altered, it is easy to store them for long periods of time. On the other hand, 140, 142, 144 between two adjacent spaces is opened by a simple operation of applying force from the outside of the pharmaceutical composition container 10. By opening them, the fluid substance 40 can be sequentially guided from the fluid substance chamber 30 to the

pharmaceutical composition chambers

32 and 34. When the flowable substance 40 is sequentially guided to the

pharmaceutical composition chambers

32 and 34, the

pharmaceutical compositions

80 and 82 are sequentially mixed with the flowable substance 40. As a result, the

pharmaceutical compositions

80 and 82 can be easily mixed in the fluid substance 40.

Further, it is desirable that the container body 20 described above includes the outer skin material 100 and the closing material 104. The outer skin material 100 becomes an outer skin of the

spaces

30, 32, 34, and 36. The occlusion material 104 occludes between two adjacent spaces, and is destroyed before the outer skin material 100 by a force applied from the outside of the pharmaceutical composition container 10.

Alternatively, it is desirable that the aforementioned skin material 100 is made of the first thermoplastic resin. In this case, the closing material 104 is made of the second thermoplastic resin. The second thermoplastic resin melts at a lower temperature than the first resin.

The outer skin material 100 is made of the first thermoplastic resin. The closing material 104 is made of the second thermoplastic resin. The second thermoplastic resin melts at a lower temperature than the first thermoplastic resin. As a result, when heated from the outside of the skin material 100, the closing material 104 can be melted without melting the skin material 100. Thereby, the restrictions regarding the operation | work for obstruct | occluding 140,142,144 between two adjacent spaces with the obstruction | occlusion material 104 decrease. As a result, the pharmaceutical composition container 10 that can be easily manufactured can be provided.

According to the present invention, a plurality of types of pharmaceutical compositions can be easily stored over a long period of time, and these pharmaceutical compositions can be easily mixed as needed.

It is a partially broken view of the pharmaceutical composition container according to the first embodiment of the present invention. It is sectional drawing of the pharmaceutical composition container concerning 1st Embodiment of this invention. It is an expanded sectional view of the pharmaceutical composition container concerning a 1st embodiment of the present invention. It is a figure which shows the manufacture procedure of the pharmaceutical composition container concerning 1st Embodiment of this invention. It is a figure which shows the usage method of the pharmaceutical composition container concerning 1st Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 2nd Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 3rd Embodiment of this invention. It is a partially broken figure of the pharmaceutical composition container concerning 4th Embodiment of this invention.

Explanation of symbols

10, 310, 510, 710

Pharmaceutical composition container

20, 320, 520

Container body

22, 522

Cover

30, 530, 830

Fluid substance chamber

32, 532

Intermediate chamber

34, 334, 534, 834 First

pharmaceutical composition chamber

36 , 336, 536, 836 Second

pharmaceutical composition chamber

38, 538 Open space 40 Fluid substance 42 First inclusion 44 Second inclusion 50 Laminate 60 Opening 80 First pharmaceutical composition 82 Second pharmaceutical composition 84 Third pharmaceutical composition 86 Fourth pharmaceutical composition 100 Skin material 102 Intermediate material 104

Occlusion material

140, 440, 640, 840 First

weak seal

142, 442, 642, 842 Second

weak seal

144, 444, 644 Third

weak Seals

146, 646 Fourth

weak seal

160, 660 Bottom

strong seal

162, 662 Side strong seal 200 Patient 33 0 Bag storage chamber 338 Dosing chamber 340 Auxiliary substance storage bag 344 Powder 350 Cutting portion 360 Opening planned portion 462 Strong seal on outer periphery

Hereinafter, embodiments of the present invention will be described with reference to the drawings. In the following description, the same parts are denoted by the same reference numerals. Their names and functions are also the same. Therefore, detailed description thereof will not be repeated.

<First embodiment>
Hereinafter, the pharmaceutical composition container 10 according to the first embodiment of the present invention will be described.

The configuration of the pharmaceutical composition container 10 according to this embodiment will be described with reference to FIG. The pharmaceutical composition container 10 according to the present embodiment includes a container body 20 and a cover 22 integrated with the container body 20. The container body 20 and the cover 22 according to the present embodiment are formed by bonding two laminated materials 50 together. The laminated material 50 will be described later.

The container body 20 includes a fluid substance chamber 30, an intermediate chamber 32, a first pharmaceutical composition chamber 34, a second pharmaceutical composition chamber 36, and an open space 38. The fluid substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 10. Yes.

The cover 22, the fluid substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, the second pharmaceutical composition chamber 36, and the open space 38 are arranged so as to form one row. As is apparent from FIG. 1, a space 38 with openings is disposed at one end of the row. A cover 22 is disposed at the other end of the row. FIG. 2 is a cross-sectional view of the pharmaceutical composition container 10 according to the present embodiment. In the form as shown in FIG. 2, the cover 22 can cover the outside of the portion of the container body 20 that forms the open space 38. This is possible because the laminated material 50 according to the present embodiment can be bent.

Referring to FIG. 1 again, the items accommodated in the fluid substance chamber 30, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36 will be described.

The fluid substance 40 is accommodated in the fluid substance chamber 30. The flowable substance 40 in this embodiment is a sterilized jelly containing moisture. In the present embodiment, the moisture content of the jelly is such that the first and

second inclusions

42 and 44 are completely from when the fluid material 40 covers the surfaces of the first and

second inclusions

42 and 44, which will be described later. It is set so that the time until melting can be secured for at least 2 minutes.

In the first pharmaceutical composition chamber 34, a first storage 42 is accommodated. In the first inclusion 42, a granular medicine or other first pharmaceutical composition 80 is contained. The material of the first inclusion 42 according to this embodiment is a starch wafer having a thickness of 15 μm.

In the second pharmaceutical composition chamber 36, the second inclusion 44 is accommodated. A second pharmaceutical composition 82 is stored in the second storage 44. The second pharmaceutical composition 82 is a substance different in kind from the granular first pharmaceutical composition 80. The material of the second inclusion 44 according to this embodiment is a starch wafer having a thickness of 10 μm. In addition, the opening of the 1st thing 42 and the 2nd thing 44 is sealed by twisting the part which corresponds to the inlet_port | entrance of the 1st pharmaceutical composition 80 or the 2nd pharmaceutical composition 82. FIG.

The reason why the oblate is used as the material of the first and

second inclusions

42 and 44 is that the functions described below are required for the first and

second inclusions

42 and 44. The function is a function in which when the flowable substance 40 covers the surface of the first inclusion 42 or the second inclusion 44, the surfaces start to melt, and after they are swallowed, they completely dissolve. The oblate used for the first inclusion 42 is thicker than the oblate used for the second inclusion 44, so that the time from the start of being covered by the flowable material 40 until it completely melts is longer than that of the second inclusion 44. This is necessary. This is necessary because the first inclusion 42 is covered with the fluid substance 40 earlier than the second inclusion 44. The reason why the 10 μm thick wafer is used as the material of the second inclusion 44 is to secure at least 2 minutes from when it is covered with the fluid substance 40 until it completely melts. Of course, the thickness of the wafer should be appropriately selected according to the material.

The fluid substance chamber 30, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36 do not affect the first pharmaceutical composition 80, the second pharmaceutical composition 82, and the fluid substance 40. Gas (for example, nitrogen gas) is sealed as necessary.

Incidentally, the intermediate chamber 32 and the open space 38 in the present embodiment are vacant until the first weak seal 140 or the fourth weak seal 146 described later is peeled off. An empty room is a space in which nothing is accommodated or a gas that does not affect the first pharmaceutical composition 80, the second pharmaceutical composition 82, or the flowable substance 40 is accommodated. The open space 38 has an opening 60. The opening 60 allows the fluidic substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, the second pharmaceutical composition chamber 36, and the outside of the open space 38 to communicate with the inside thereof. However, until the first weak seal 140 to the fourth weak seal 146 are all peeled off, the opening 60 has the fluid substance chamber 30, the intermediate chamber 32, the first pharmaceutical composition chamber 34, and the second pharmaceutical composition chamber 36. Among these, the inside of what communicates with the space 38 with an opening is communicated with the outside of those spaces.

The fluid material chamber 30 and the intermediate chamber 32 are partitioned by a first weak seal 140. The intermediate chamber 32 and the first pharmaceutical composition chamber 34 are partitioned by a second weak seal 142. The first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 are partitioned by a third weak seal 144. A space between the second pharmaceutical composition chamber 36 and the open space 38 is partitioned by a fourth weak seal 146. The first weak seal 140, the second weak seal 142, the third weak seal 144, and the fourth weak seal 146 (these are collectively referred to as “first weak seal 140 to fourth weak seal 146”) are the container body 20. It is arrange | positioned in the part which hits between two adjacent things among the space with which is equipped.

The strength of the first weak seal 140 to the fourth weak seal 146 is lower than the strength of the bottom strong seal 160 and the strength of the side strong seal 162. The bottom strong seal 160 is a portion where the surfaces of the laminated material 50 are bonded to each other at the boundary between the container body 20 and the cover 22. The side strong seal 162 is a portion excluding the first weak seal 140 to the fourth weak seal 146 and the bottom strong seal 160 in the portion where the surfaces of the laminated material 50 are bonded to each other. In the case of this embodiment, the strength of the first weak seal 140 to the fourth weak seal 146 is the pressure of the fluid material 40 (this pressure is due to the fact that an adult applies force from outside the fluid material chamber 30). ) That can be destroyed by In addition, between the fluid substance chamber 30 and the intermediate chamber 32, between the intermediate chamber 32 and the first pharmaceutical composition chamber 34, between the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36, and The specific method for breaking the space between the second pharmaceutical composition chamber 36 and the open space 38 is not limited to the method of breaking by the pressure of the flowable substance 40. For example, the first weak seal 140 to the fourth weak seal 146 may be torn by pinching and pulling the two laminated materials 50 with both hands.

FIG. 3 is an enlarged cross-sectional view of the pharmaceutical composition container 10 according to the present embodiment. The configuration of the laminated material 50 and the configurations of the first weak seal 140 to the fourth weak seal 146 will be described with reference to FIGS. 1 and 3. The laminated material 50 according to the present embodiment includes an outer skin material 100, an intermediate material 102, and a closing material 104 (Note that these three-layer structures of the laminated material 50 are not shown in FIG. 2 and are omitted. Have been). The closing

materials

104, 104 of the two laminated materials 50 are fused to each other. This fused portion is destroyed prior to the skin material 100 and the intermediate material 102 by the force applied from the outside of the pharmaceutical composition container 10. Compared to the melting point of the skin member 100 and the melting point of the intermediate member 102, the melting point of the closing member 104 is low. Therefore, when heat is applied to the laminated material 50 from the outside of the skin material 100, the closing material 104 is melted before the skin material 100 and the intermediate material 102 are melted. Since the closing material 104 is melted before the outer skin material 100 and the intermediate material 102 are melted, only the closing material 104 can be fused. This fused portion is the first weak seal 140 to the fourth weak seal 146. Only the fourth weak seal 146 is shown in FIG.

The material of the closing material 104 corresponding to the first weak seal 140 to the fourth weak seal 146 is different from the material of the closing material 104 corresponding to the bottom strong seal 160 and the side strong seal 162 (however, the material of the outer skin material 100 and The material of the intermediate member 102 is the same between the portion corresponding to the first weak seal 140 to the fourth weak seal 146 and the portion corresponding to the bottom strong seal 160 and the side strong seal 162). Since they are different, the strength of the first weak seal 140 to the fourth weak seal 146 can be made lower than the strength of the bottom strong seal 160 and the strength of the side strong seal 162. Incidentally, in the present embodiment, the material of the outer skin material 100 is polyethylene terephthalate. The material of the intermediate material 102 is nylon. The material of the portion corresponding to the first weak seal 140 to the fourth weak seal 146 in the closing material 104 is polyethylene.

FIG. 4 is a diagram showing a manufacturing procedure of the pharmaceutical composition container 10 according to the present embodiment. The manufacturing procedure of the pharmaceutical composition container 10 will be described with reference to FIG. The first step is a step of superimposing the two

laminated materials

50 and 50 and heating the portion corresponding to the side portion of the pharmaceutical composition container 10. Thereby, as shown in FIG. 4A, the side strong seal 162 is formed. The second step is a step of heating the vicinity of the intermediate chamber 32 in the laminated material 50. As a result, as shown in FIG. 4B, a first weak seal 140 and a second weak seal 142 are formed. A 3rd step is a step which inserts the 1st inclusion 42 between the two

laminated materials

50 and 50, as FIG.4 (C) shows. The fourth step is a step of heating the vicinity of the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 in the laminated material 50. Thereby, the 3rd weak seal | sticker 144 is formed as FIG.4 (D) shows. The fifth step is a step of inserting the second inclusion 44 between the two

laminated materials

50 and 50 as shown in FIG. 4 (E). The sixth step is a step of heating the area between the second pharmaceutical composition chamber 36 and the open space 38 in the laminated material 50. Thereby, as shown in FIG. 4F, a fourth weak seal 146 is formed. The seventh step is a step of filling the fluid material 40 between the two laminated materials 50. At this time, first, the portion of the first weak seal 140 in the container body 20 is bent, and the fluid substance chamber 30 is directed upward. When the fluid material chamber 30 faces upward, a nozzle (not shown) is inserted into the fluid material chamber 30 to fill the fluid material 40. The eighth step is a step of heating the boundary portion between the container body 20 and the cover 22. As a result, the bottom strong seal 160 is formed as shown in FIG. In the ninth step, as shown in FIG. 4 (H), after the boundary portion between the container body 20 and the cover 22 is bent, the portion of the container body 20 that forms the open space 38 is formed between the cover 22. It is a step to insert into. The pharmaceutical composition container 10 completed through these steps is stored in a paper box (not shown) and distributed.

FIG. 5 is a diagram showing a method of using the pharmaceutical composition container 10 according to the present embodiment. The procedure for taking out the first pharmaceutical composition 80 and the second pharmaceutical composition 82 from the pharmaceutical composition container 10 and taking them will be described with reference to FIG.

First, a caregiver or the like pulls out the distal end portion of the container main body 20 from the cover 22 so that the pharmaceutical composition container 10 in the form shown in FIG. 4 (H) is shown in FIG. 1 or FIG. 4 (G). In the form shown in Next, a caregiver or the like pushes the fluid substance chamber 30 from the outside of the pharmaceutical composition container 10 and peels the first weak seal 140 by the pressure of the fluid substance 40. When the first weak seal 140 is peeled off, the fluid material 40 is pushed out to the intermediate chamber 32. The extruded fluid material 40 fills the intermediate chamber 32.

In this state, when a caregiver or the like continues to push the fluid substance chamber 30 from the outside of the pharmaceutical composition container 10, the second weak seal 142 is peeled off by the pressure of the fluid substance 40 inside the intermediate chamber 32. At this time, the cover 22 is folded toward the container body 20. When the second weak seal 142 is peeled off, the fluid substance 40 is pushed out into the first pharmaceutical composition chamber 34. The extruded fluid material 40 fills the first pharmaceutical composition chamber 34. From this time, the surface of the first inclusion 42 starts to melt by the fluid material 40.

After the fluid substance 40 is pushed out to the first pharmaceutical composition chamber 34, a caregiver or the like causes the patient 200 to hold the pharmaceutical composition container 10. When the pharmaceutical composition container 10 is prepared, the patient 200 further folds the cover 22 folded toward the container body 20 toward the container body 20, and squeezes the container body 20 and the cover 22. Thereby, pressure is applied to the fluid substance 40. As a result of the pressure applied to the fluid substance 40, the third weak seal 144 is peeled off. When the third weak seal 144 is peeled off, the fluid substance 40 together with the first inclusion 42 is pushed out into the second pharmaceutical composition chamber 36. The extruded fluid material 40 fills the second pharmaceutical composition chamber 36. From this time, the surface of the second inclusion 44 also starts to melt by the fluid material 40.

After the fluid substance 40 is pushed out into the second pharmaceutical composition chamber 36, the patient 200 further folds the container body 20 and the cover 22 in the direction from the fluid substance chamber 30 toward the second pharmaceutical composition chamber 36, And squeeze them further. Thereby, pressure is applied to the fluid substance 40. As a result of the pressure being applied to the fluid material 40, the fourth weak seal 146 peels off. When the fourth weak seal 146 is peeled off, the fluid substance 40, the first inclusion 42, and the second inclusion 44 are pushed out into the open space 38. They are swallowed through the open space 38 and the patient's 200 mouth. At this time, since the surfaces of the first inclusion 42 and the second inclusion 44 are dissolved in the components of the fluid substance 40, the surfaces of the first inclusion 42 and the second inclusion 44 are easy to slip. Since the surface of the 1st thing 42 and the 2nd thing 44 becomes easy to slip, the 1st thing 42 and the 2nd thing 44 are swallowed smoothly.

As described above, the pharmaceutical composition container 10 according to the present embodiment has the following eight effects. The first effect is that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be swallowed easily. The second effect is an effect that the bitterness of the drug is suppressed. The third effect is an effect that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be prevented from scattering in the mouth. The fourth effect is that there is no need to worry about the stability of the first pharmaceutical composition 80 and the second pharmaceutical composition 82. The fifth effect is an effect that various kinds of solids can be taken by a person who has difficulty in swallowing. The sixth effect is an effect that cleanliness when taking the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be improved. The seventh effect is that the first and

second items

42 and 44 can be pushed out smoothly. The eighth effect is that the residual amount of the

pharmaceutical compositions

80 and 82 inside the pharmaceutical composition container 10 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). It is.

The first effect will be described in detail. The first storage 42 and the second storage 44 enter the mouth of the patient 200 while being wrapped in the fluid substance 40. At this time, the surfaces of the first inclusion 42 and the second inclusion 44 are melted. Since the surface is melted while being wrapped in the fluid substance 40, even the patient 200 who is difficult to swallow can easily swallow the first and

second inclusions

42 and 44. Since the first stored product 42 and the second stored product 44 contain the pharmaceutical composition 80, swallowing the first stored product 42 and the second stored product 44 allows the first stored pharmaceutical product 80 and the second stored pharmaceutical composition 44. The object 82 is also swallowed. Thereby, the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 can be swallowed easily.

The second effect will be described in detail. As described above, the first collection 42 and the second collection 44 enter the mouth of the patient 200 in a state of being wrapped in the fluid substance 40. As a result, the first pharmaceutical composition 80 and the second pharmaceutical composition 82, which are the contents of the first inclusion 42 and the second inclusion 44, are obtained from the fluid substance 40, the first inclusion 42, and the second inclusion 44. Will be double wrapped. Since the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are doubly wrapped, even if the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are drugs, the tongue of the patient 200 has a bitter taste. The possibility of feeling is reduced. As a result, the bitterness of the drug is suppressed.

The third effect will be described in detail. As described above, the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are double-wrapped by the fluid substance 40, the first inclusion 42 and the second inclusion 44. Thereby, possibility that the 1st pharmaceutical composition 80 and the 2nd pharmaceutical composition 82 will scatter in the mouth of the patient 200 becomes low. As a result, scattering of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 in the mouth can be suppressed.

The fourth effect will be described in detail. The first pharmaceutical composition 80 and the second pharmaceutical composition 82 are chemical substances. When chemical substances come into contact, chemical reactions often occur. Due to the chemical reaction, the pharmaceutical composition loses its action as a medicine. For this reason, in many cases, a plurality of pharmaceutical compositions cannot be stored in a mixed state. When storing them in a mixed state, it is necessary to check beforehand whether their effects are lost. The pharmaceutical composition container 10 according to the present embodiment is provided with a plurality of spaces. It is substantially the same to store a single pharmaceutical composition in each space and to store a plurality of pharmaceutical compositions separately. This is the reason why it is not necessary to worry about the stability of the pharmaceutical composition if the pharmaceutical composition container 10 according to the present embodiment is used. Since there is no need to worry about the stability of the pharmaceutical composition, there is no need to examine in advance whether the efficacy of a plurality of pharmaceutical compositions has been lost.

The fifth effect will be described. After sequentially inducing the fluid substance 40 into the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36, swallowing the fluid substance 40, the first inclusion 42 and the second inclusion 44, The activity of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 itself does not have much influence on the difficulty of swallowing. Thereby, various kinds of solids can be taken for those who have difficulty in swallowing.

The sixth effect will be described. Prior to use of the pharmaceutical composition container 10, a portion of the container body 20 that forms the open space 38 is covered with the cover 22. Thereby, the frequency with which bacteria etc. adhere to the part which forms the space 38 with an opening among the container main bodies 20 becomes low. In particular, compared to the case where the opening of the container body 20 that touches the mouth is formed, the frequency of attachment of bacteria or the like is lower. When an opening is formed by destroying a portion of the container body 20 that touches the mouth, it is necessary to touch that portion with an instrument or hand when destroying that portion. This is because bacteria and viruses attached to these instruments and hands may adhere to the parts. In the case of the pharmaceutical composition container 10 according to the present embodiment, the fluid substance 40, the first inclusion 42, and the second inclusion 44 can be swallowed by breaking the first weak seal 140 to the fourth weak seal 146. Since it is not necessary to touch the portion of the container body 20 that touches the mouth with an instrument or hand, the possibility of attachment of bacteria or viruses can be reduced. As a result, cleanliness when taking the first pharmaceutical composition 80 and the second pharmaceutical composition 82 can be improved.

The seventh effect will be described. The end portion of the first pharmaceutical composition chamber 34 on the second pharmaceutical composition chamber 36 side becomes narrower as it approaches the second pharmaceutical composition chamber 36, and the first encapsulating is contained in the first pharmaceutical composition chamber 34. Since the thing 42 is accommodated, when extruding the 1st inclusion 42 by the fluid substance 40, it can implement smoothly. The end of the second pharmaceutical composition chamber 36 on the side of the open space 38 is narrowed as it approaches the open space 38, and the second inclusion 44 is accommodated in the second pharmaceutical composition chamber 36. Therefore, the second inclusion 44 is also pushed out with the same smoothness.

The eighth effect will be described. When the fluid material 40, the first inclusion 42 and the second inclusion 44 are pushed out from the opening 60, the first pharmaceutical composition 80 and the second pharmaceutical composition 82 therein are also pushed out at the same time. As a result, the remaining amounts of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 in the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 are set to the first and

second inclusions

42 and 44, respectively. Compared to the case where the first pharmaceutical composition 80 and the second pharmaceutical composition 82 are not contained in the container. Moreover, the first and

second items

42 and 44 according to this embodiment are sealed. Since it is sealed, the possibility that the first pharmaceutical composition 80 and the second pharmaceutical composition 82 leak out of the first and

second inclusions

42 and 44 is extremely low. Since the possibility is very low, the residual amount of the first pharmaceutical composition 80 and the second pharmaceutical composition 82 inside the pharmaceutical composition container 10 is reduced (actually, the residual amount is made an amount close to zero). be able to.

<Second Embodiment>
Hereinafter, the pharmaceutical composition container 310 according to the second embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment. In the present embodiment, detailed description thereof will not be repeated.

FIG. 6 is a partially cutaway view of the pharmaceutical composition container 310 according to the present embodiment. The configuration of the pharmaceutical composition container 310 according to this embodiment will be described with reference to FIG. The pharmaceutical composition container 310 according to the present embodiment includes a container body 320 and an auxiliary substance storage bag 340. Similar to the first embodiment, the container body 320 is formed by bonding two laminated materials 50 together.

The container main body 320 has a bag storage chamber 330, a first pharmaceutical composition chamber 334, a second pharmaceutical composition chamber 336, and a dosing chamber 338. The bag storage chamber 330, the first pharmaceutical composition chamber 334, the second pharmaceutical composition chamber 336, and the dosing chamber 338 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 310. .

In the bag storage chamber 330, the auxiliary substance storage bag 340 described above is stored. The auxiliary substance storage bag 340 is fixed in the bag storage chamber 330 by an outer peripheral strong seal 462 described later. The auxiliary substance storage bag 340 is formed of the same laminated material 50 as the container main body 320.

The auxiliary substance accommodation bag 340 contains the fluid substance 40. The strength of one end of the auxiliary substance storage bag 340 facing the first weak seal 440 described later has the same structure as that of the first weak seal 140 to the fourth weak seal 146 according to the first embodiment. . Therefore, this part can be destroyed by the pressure of the flowable substance 40. The fluid substance 40 is sterilized together with the auxiliary substance storage bag 340 and then sandwiched between the above-described laminated materials 50. Thereafter, the outer peripheral strong seal 462 is formed, so that the other end of the auxiliary substance storage bag 340 is bonded to the outer peripheral strong seal 462.

In the first pharmaceutical composition chamber 334, the first inclusion 42 is accommodated. The powder 344 is accommodated in the second pharmaceutical composition chamber 336. Until the first weak seal 440 to the third weak seal 444 are peeled off, the dosing chamber 338 in this embodiment is an empty room.

The bag storage chamber 330 and the first pharmaceutical composition chamber 334 are partitioned by a first weak seal 440. The first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 are partitioned by a second weak seal 442. The second pharmaceutical composition chamber 336 and the dosing chamber 338 are partitioned by a third weak seal 444. The first weak seal 440 to the third weak seal 444 are arranged in a portion between two adjacent ones of the space formed by the container main body 320.

The strength of the first weak seal 440 to the third weak seal 444 is lower than the strength of the outer peripheral strong seal 462. The outer peripheral strong seal 462 is a portion where the edge of the container body 320 is bonded. The strength of the first weak seal 440 to the third weak seal 444 is a strength that can be broken by the pressure of the fluid material 40 (this pressure is caused by an adult applying force from the outside of the bag housing chamber 330). is there. Note that the specific method for breaking the first weak seal 440 to the third weak seal 444 is not limited to the method of breaking by the pressure of the fluid substance 40. For example, the first weak seal 140 to the fourth weak seal 146 may be torn by pinching and pulling two laminated materials forming the container body 20 with both hands.

The configuration of the laminated material according to this embodiment and the configuration of the first weak seal 440 to the third weak seal 444 are the same as those of the first embodiment. The configuration of the outer peripheral strong seal 462 is the same as the configuration of the bottom strong seal 160 and the side strong seal 162 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

A pair of incisions 350 made of V-shaped cuts are formed on both sides of the dosing chamber 338. The opening formation scheduled portion 360 sandwiched between the cut portions 350 is a portion where the opening is scheduled to be formed. This opening allows the outside and inside of the medication chamber 338 to communicate.

The manufacturing procedure of the pharmaceutical composition container 310 according to this embodiment will be described. The first step is a step of heating the outer edge of the laminated material 50. However, the portion where the auxiliary substance storage bag 340 is sandwiched is not heated. Thereby, the outer periphery strong seal | sticker 462 is formed. The second step is a step of heating the vicinity of the first weak seal 440 in the laminated material 50. Thereby, the first weak seal 440 is formed. The third step is a step of inserting the first inclusion 42 between the laminated materials 50. The fourth step is a step of heating the area between the first pharmaceutical composition chamber 334 and the second pharmaceutical composition chamber 336 in the laminated material 50. As a result, the second weak seal 442 is formed. The fifth step is a step of filling powder 344 between the laminated materials 50. The sixth step is a step of heating the area between the second pharmaceutical composition chamber 336 and the dosing chamber 338 in the laminated material 50. Thereby, the third weak seal 444 is formed. The seventh step is a step of inserting the auxiliary substance storage bag 340 between the laminated materials 50. At this time, first, the portion of the first weak seal 440 in the laminated material 50 is bent, and the opening of the bag storage chamber 330 faces upward. When the opening of the bag storage chamber 330 faces upward, the bag storage chamber 330 is opened wide, and the auxiliary substance storage bag 340 is inserted therein. The eighth step is a step of heating a portion of the outer edge of the laminated material 50 where the auxiliary substance storage bag 340 is sandwiched. The ninth step is a step of forming the cut portion 350. The pharmaceutical composition container 310 completed through these steps is stored in a paper box (not shown) and distributed.

The method of using the pharmaceutical composition container 310 according to the present embodiment is the first implementation except that instead of pulling out the distal end portion of the container body 20 from the cover 22, the area around the notch 350 is sheared to form an opening. It is the same as that of the usage method of the pharmaceutical composition container 10 concerning a form. Therefore, detailed description thereof will not be repeated here.

As described above, the pharmaceutical composition container 310 according to the present embodiment has the following three effects. The first effect is that the granular drug or other pharmaceutical composition 80 can be swallowed easily. The second effect is that there is no need to worry about the stability of the drug. These are the same as some of the effects of the pharmaceutical composition container 10 according to the first embodiment. The third effect is that the residual amount of the pharmaceutical composition 80 inside the pharmaceutical composition container 210 can be reduced (in the case of this embodiment, the residual amount can be made an amount close to zero). .

<Third embodiment>
Hereinafter, the pharmaceutical composition container 510 according to the third embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment and 2nd Embodiment. In the present embodiment, detailed description thereof will not be repeated.

FIG. 7 is a partially cutaway view of the pharmaceutical composition container 510 according to the present embodiment. The configuration of the pharmaceutical composition container 510 according to the present embodiment will be described with reference to FIG. A pharmaceutical composition container 510 according to this embodiment includes a container body 520 and a cover 522 integrated with the container body 520. Unlike the first embodiment, the container main body 520 and the cover 522 according to the present embodiment are formed by folding one laminated material 50 in two and bonding the outer periphery together. In FIG. 7, the hatching at the right end of the pharmaceutical composition container 510 indicates a cross section of the laminated material 50.

The pharmaceutical composition container 510 includes a fluid substance chamber 530, an intermediate chamber 532, a first pharmaceutical composition chamber 534, a second pharmaceutical composition chamber 536, and an open space 538. The fluid substance chamber 530, the intermediate chamber 532, the first pharmaceutical composition chamber 534, and the second pharmaceutical composition chamber 536 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 510. Yes. The cover 522 can cover the outside of the portion of the container body 520 that forms the open space 538.

In the first pharmaceutical composition chamber 534, the third pharmaceutical composition 84 is accommodated. The third pharmaceutical composition 84 in this embodiment is a powder medicine. A fourth pharmaceutical composition 86 is accommodated in the second pharmaceutical composition chamber 536. The fourth pharmaceutical composition 86 in this embodiment is a different type of powder from the third pharmaceutical composition 84. Of course, it goes without saying that granular medicines and other substances may be accommodated in the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536.

As in the first embodiment, the fluid substance chamber 530, the first pharmaceutical composition chamber 534, and the second pharmaceutical composition chamber 536 include the third pharmaceutical composition 84, the fourth pharmaceutical composition 86, and the fluid substance 40. Gas that does not affect the air is sealed as necessary.

As in the first embodiment, the intermediate chamber 532 and the open space 538 are empty until the first weak seal 640 to the fourth weak seal 646 are peeled off. The open space 538 has an opening.

The fluid material chamber 530 and the intermediate chamber 532 are partitioned by a first weak seal 640. The intermediate chamber 532 and the first pharmaceutical composition chamber 534 are partitioned by a second weak seal 642. The first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536 are partitioned by a third weak seal 644. A space between the second pharmaceutical composition chamber 536 and the open space 538 is partitioned by a fourth weak seal 646.

The strength of the first weak seal 640 to the fourth weak seal 646 is lower than the strength of the bottom strong seal 660 and the strength of the side strong seal 662. In the case of this embodiment, the strength of the first weak seal 640 to the fourth weak seal 646 is the pressure of the fluid substance 40 (this pressure is due to the force applied by the adult from outside the fluid substance chamber 30). ) That can be destroyed by In addition, between the fluid substance chamber 530 and the intermediate chamber 532, between the intermediate chamber 532 and the first pharmaceutical composition chamber 534, between the first pharmaceutical composition chamber 534 and the second pharmaceutical composition chamber 536, and The specific method for breaking the space between the second pharmaceutical composition chamber 536 and the open space 538 is not limited to the method of breaking by the pressure of the flowable substance 40.

The method of using the pharmaceutical composition container 510 according to the present embodiment is the same as the method of using the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

As described above, the pharmaceutical composition container 510 according to this embodiment has the following three effects. A 1st effect is an effect that a powder medicine and other pharmaceutical compositions can be swallowed easily. The second effect is that there is no need to worry about the stability of the drug. The third effect is that the pharmaceutical composition container 510 according to the present embodiment is used to swallow the pharmaceutical composition by providing a step at a portion adjacent to the third weak seal 644 in the side strong seal 662. This is an effect of preventing the tip of the pharmaceutical composition container 510 from entering the mouth of the patient 200 too much.

<Fourth embodiment>
Hereinafter, the pharmaceutical composition container 710 according to the fourth embodiment of the present invention will be described. In addition, the same code | symbol is attached | subjected to the same thing as what was demonstrated in 1st Embodiment thru | or 3rd Embodiment. In the present embodiment, detailed description thereof will not be repeated.

FIG. 8 is a partially cutaway view of the pharmaceutical composition container 710 according to the present embodiment. Similar to the first embodiment, the pharmaceutical composition container 710 according to the present embodiment is formed by bonding two laminated materials 50 together.

The pharmaceutical composition container 710 includes a fluid substance chamber 830, a first pharmaceutical composition chamber 834, and a second pharmaceutical composition chamber 836. The fluid substance chamber 830, the first pharmaceutical composition chamber 834, and the second pharmaceutical composition chamber 836 are formed so as to be airtight with respect to the external space around the pharmaceutical composition container 710.

In the first pharmaceutical composition chamber 834, the third pharmaceutical composition 84 is accommodated. A fourth pharmaceutical composition 86 is accommodated in the second pharmaceutical composition chamber 836. Needless to say, the first pharmaceutical composition chamber 834 and the second pharmaceutical composition chamber 836 may contain granular drugs and other substances.

Similar to the first embodiment, the fluid substance chamber 830, the first pharmaceutical composition chamber 834, and the second pharmaceutical composition chamber 836 include the third pharmaceutical composition 84, the fourth pharmaceutical composition 86, and the fluid substance 40. Gas that does not affect the air is sealed as necessary.

The fluid substance chamber 830 and the first pharmaceutical composition chamber 834 are partitioned by a first weak seal 840. The first pharmaceutical composition chamber 834 and the second pharmaceutical composition chamber 836 are partitioned by a second weak seal 842.

The strengths of the first weak seal 840 and the second weak seal 842 are the seals forming the outer peripheral parts of the fluid substance chamber 830, the first pharmaceutical composition chamber 834, and the second pharmaceutical composition chamber 836 (first weak seal). It is lower than the strength of the seal 840 and the second weak seal 842).

The method of using the pharmaceutical composition container 710 according to the present embodiment is the same as the method of using the pharmaceutical composition container 10 according to the first embodiment. Therefore, detailed description thereof will not be repeated here.

As described above, the pharmaceutical composition container 710 according to this embodiment has the following two effects. A 1st effect is an effect that a powder medicine and other pharmaceutical compositions can be swallowed easily. The second effect is that there is no need to worry about the stability of the drug.

The

pharmaceutical composition containers

10, 310, 510, and 710 described in the present embodiment are illustrated in order to embody the technical idea of the present invention. This does not limit the material of the

container body

20, 320, 520 to the above-described embodiment. This does not limit the shape of the container

main body

20, 320, 520, the shape of each space, the shape of the opening, their dimensions, their structure, and their arrangement to the above-described embodiments. The

pharmaceutical composition containers

10, 310, 510, and 710 can be variously modified within the scope of the technical idea of the present invention.

For example, the forms of the first inclusion 42 and the second inclusion 44 are not limited to those described above. For example, the outer shape may be a rectangle. Moreover, it replaces with the 1st thing 42 and the 2nd thing 44, and the well-known capsule may be accommodated.

Also, the number of spaces provided in one pharmaceutical composition container may be larger than the number of spaces that the

pharmaceutical composition containers

10, 310, 510, 710 have.

In addition, the shape of the space provided in one pharmaceutical composition container is not particularly limited. For example, the first pharmaceutical composition chamber 34 and the second pharmaceutical composition chamber 36 shown in FIG. 1 have a hexagonal shape, which may be a triangle, a rectangle, a pentagon, a heptagon or more polygon. It may be circular or elliptical.

Further, the pharmaceutical composition container 310 according to the second embodiment may be provided with an empty room similar to the intermediate chamber 32 according to the first embodiment, or the intermediate chamber 32 according to the first embodiment is not provided. May be.

The pharmaceutical composition container 10 according to the first embodiment, the pharmaceutical composition container 310 according to the second embodiment, and the pharmaceutical composition container 710 according to the fourth embodiment are limited to those in which the laminated materials 50 are bonded to each other. Not. The pharmaceutical composition container 10 according to the first embodiment, the pharmaceutical composition container 310 according to the second embodiment, and the pharmaceutical composition container 710 according to the fourth embodiment are obtained by folding one sheet-like laminated material 50 into two. The outer edges may be bonded together. The pharmaceutical composition container 510 according to the third embodiment is not limited to the one in which one laminated material 50 is folded in two and the outer circumferences are bonded together.

In addition, in the pharmaceutical composition container 310 described above, the cut portion 350 is configured with a V-shaped cut, but the cut portion of the present invention may have a shape other than the V shape.

In each of the above embodiments, the case where the pharmaceutical composition is a powder or a granule and the fluid substance is jelly has been described. However, the pharmaceutical composition and the fluid substance applied to the present invention are not limited thereto. Needless to say. For example, the pharmaceutical composition may be a tablet, a capsule or a simple lump in addition to a powder or a granule. The pharmaceutical composition may not be accommodated in the first pharmaceutical composition chamber 34 or the second pharmaceutical composition chamber 36 in the form of a inclusion. That is, the pharmaceutical composition does not have to be wrapped by wafers or other packaging materials. Furthermore, the thing shape | molded as a pharmaceutical composition is not limited to the thing normally handled as a pharmaceutical. For example, the product molded as a pharmaceutical composition may be a food that has been recognized to improve health. The flowable substance may be honey, custard cream, peanut spread, cheese spread, etc. in addition to an aqueous solution. However, the fluid substance needs fluidity to such an extent that it can go back and forth in the space provided in the container body under the environment where the pharmaceutical composition container is used.

By the way, if it is confirmed that the pharmaceutical composition does not change during distribution or storage of the pharmaceutical composition, a mixture of the pharmaceutical composition is contained in one pharmaceutical composition chamber. Also good.

When the inclusion is stored in the pharmaceutical composition container, the inclusion is made of various materials that have been conventionally used as an edible film material in addition to the above-described starch-oblate having a thickness of 15 μm. Can be used. These materials include polysaccharides (eg, pullulan, arabinoxylan, guar gum degradation products, sodium alginate, carrageenan, agar, pectin, cellulose, etc.) and peptide substances (eg, gelatin, silk protein degradation products, casein) Decomposition products). These materials can be used alone or in combination of two or more.

The pharmaceutical composition container according to the present invention can be suitably used as a container for taking medicine. In particular, the container for taking medicine can be suitably used for a medicine filled by the following system. The system is a system in which a plurality of auger filling machines are installed, a transport system and a weighing system are added, and connected to a pharmaceutical production line to perform automatic operation for a long time.

Claims

A pharmaceutical composition container comprising at least three spaces in the container body,
The space between two adjacent spaces is closed,
The space between the two adjacent spaces opens when a force is applied from the outside of the pharmaceutical composition container,
A fluid substance is accommodated in a fluid substance chamber which is at least one of the spaces,
A pharmaceutical composition container, wherein different types of pharmaceutical compositions are accommodated in each of the pharmaceutical composition chambers that are at least two of the spaces.
The container body is
An outer skin material serving as an outer skin of the space;
It has the obstruction | occlusion material obstruct | occluded before the said outer_shell | closure material by the force applied from the exterior of the said pharmaceutical composition container, and obstruct | occludes between the said two adjacent spaces. Item 10. A pharmaceutical composition container according to Item 1.
The outer skin material is made of the first thermoplastic resin,
The pharmaceutical composition container according to claim 2, wherein the occlusive material is made of a second thermoplastic resin that melts at a lower temperature than the first thermoplastic resin.